- In May 2024, Biocatalysts Ltd announced the successful large-scale production of a specialized ligase enzyme for a leading pharmaceutical company. The enzyme was purified using a state-of-the-art chromatography system, which was recently installed at the company’s Cardiff facility to enhance post-fermentation processing capabilities
- In February 2024, Codexis, Inc. announced a new agreement with Roche, granting Roche an exclusive global license for its newly engineered double-stranded DNA (dsDNA) ligase, specifically designed for next-generation sequencing (NGS) library preparation, along with the Company’s EvoT4 DNA ligase. As part of the agreement, Codexis will receive upfront payments and technical milestone-based compensation. This new deal replaces the previous exclusive license agreement for the EvoT4 DNA ligase
- In February 2023, Ajinomoto Bio-Pharma Services announced the successful development of a novel enzyme for efficient double-stranded oligonucleotide formation. Collaborating with researchers from the University of Shizuoka, the company engineered a highly functional artificial RNA ligase using an ancestral design approach. This newly developed ligase demonstrated significantly enhanced thermostability and superior ligation activity, particularly for RNA fragments containing xenonucleic acids, outperforming natural RNA ligases in both efficiency and stability
